BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 25467150)

  • 1. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
    Zhang P; Li S; Gao Y; Lu W; Huang K; Ye D; Li X; Chu Y
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5639-5643. PubMed ID: 25467150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
    Zhang P; Hu HR; Huang ZH; Lei JY; Chu Y; Ye DY
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7232-6. PubMed ID: 23099099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and anti-inflammatory evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
    Gao Y; Zhang P; Cui A; Ye DY; Xiang M; Chu Y
    Bioorg Med Chem; 2018 Nov; 26(20):5479-5493. PubMed ID: 30293796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
    Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer.
    Gao Y; Ye DY; Zhou WC; Chu Y
    Eur J Med Chem; 2017 Jul; 135():370-381. PubMed ID: 28460311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
    Zhang P; Hu HR; Bian SH; Huang ZH; Chu Y; Ye DY
    Eur J Med Chem; 2013 Mar; 61():95-103. PubMed ID: 23047001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin.
    Bidon-Chanal A; Fuertes A; Alonso D; Pérez DI; Martínez A; Luque FJ; Medina M
    Eur J Med Chem; 2013 Feb; 60():479-89. PubMed ID: 23354070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
    Arfeen M; Patel R; Khan T; Bharatam PV
    J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo.
    Tapia-Rojas C; Schüller A; Lindsay CB; Ureta RC; Mejías-Reyes C; Hancke J; Melo F; Inestrosa NC
    Biochem J; 2015 Mar; 466(2):415-30. PubMed ID: 25423492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.
    Mohammad MK; Al-Masri IM; Taha MO; Al-Ghussein MA; Alkhatib HS; Najjar S; Bustanji Y
    Eur J Pharmacol; 2008 Apr; 584(1):185-91. PubMed ID: 18295757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
    Darshit BS; Balaji B; Rani P; Ramanathan M
    J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
    Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
    J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of small molecules that inhibit GSK-3beta through virtual screening.
    Kang NS; Lee GN; Kim CH; Bae MA; Kim I; Cho YS
    Bioorg Med Chem Lett; 2009 Jan; 19(2):533-7. PubMed ID: 19081248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidating substrate and inhibitor binding sites on the surface of GSK-3β and the refinement of a competitive inhibitor.
    Licht-Murava A; Plotkin B; Eisenstein M; Eldar-Finkelman H
    J Mol Biol; 2011 Apr; 408(2):366-78. PubMed ID: 21354422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of glycogen synthase kinase-3beta improves tolerance to ischemia in hypertrophied hearts.
    Barillas R; Friehs I; Cao-Danh H; Martinez JF; del Nido PJ
    Ann Thorac Surg; 2007 Jul; 84(1):126-33. PubMed ID: 17588398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site.
    Rippin I; Khazanov N; Shirley Ben Joseph ; Kudinov T; Berent E; Arciniegas Ruiz SM; Marciano D; Levy L; Gruzman A; Senderowitz H; Eldar-Finkelman H
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of 1-phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as new glycogen synthase kinase-3β inhibitors.
    La Pietra V; La Regina G; Coluccia A; Famiglini V; Pelliccia S; Plotkin B; Eldar-Finkelman H; Brancale A; Ballatore C; Crowe A; Brunden KR; Marinelli L; Novellino E; Silvestri R
    J Med Chem; 2013 Dec; 56(24):10066-78. PubMed ID: 24295046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Famotidine inhibits glycogen synthase kinase-3β: an investigation by docking simulation and experimental validation.
    Mohammad M; Al-Masri IM; Issa A; Al-Ghussein MA; Fararjeh M; Alkhatib H; Taha MO; Bustanji Y
    J Enzyme Inhib Med Chem; 2013 Aug; 28(4):690-4. PubMed ID: 22512725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naproxen and cromolyn as new glycogen synthase kinase 3β inhibitors for amelioration of diabetes and obesity: an investigation by docking simulation and subsequent in vitro/in vivo biochemical evaluation.
    Motawi TM; Bustanji Y; El-Maraghy SA; Taha MO; Al Ghussein MA
    J Biochem Mol Toxicol; 2013 Sep; 27(9):425-36. PubMed ID: 23784744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation.
    Bustanji Y; Taha MO; Almasri IM; Al-Ghussein MA; Mohammad MK; Alkhatib HS
    J Enzyme Inhib Med Chem; 2009 Jun; 24(3):771-8. PubMed ID: 18720192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.